Veracyte (VCYT) 47th Annual Raymond James Institutional Investor Conference summary

Strategic Vision and Platform Approach

• Focus on transforming global cancer care through advanced molecular diagnostics and a platform approach spanning multiple cancer types and care stages.

• Emphasis on generating extensive data to drive clinical insights, research, and adoption, creating a flywheel effect for long-term growth.

• Over 800,000 patients served and more than 600 publications supporting clinical utility.

• Strategic focus on phased growth drivers across Afirma, Decipher, Prosigna, TrueMRD, and IVDs for near-, mid-, and long-term expansion.

2025 Performance and Operational Achievements

• Achieved $517 million in revenue with 18% testing revenue growth, led by Afirma and Decipher franchises.

• Surpassed 25% adjusted EBITDA margin target, reaching 27.6% in 2025, and improved operational efficiency through restructuring and platform upgrades.

• Completed key product launches and restructuring, including Decipher for metastatic patients and transition of Afirma to v2 transcriptome.

• Demonstrated strong revenue growth from $297M in 2022 to $517M in 2025, with adjusted EBITDA margin rising from 8.3% to 27.6%.

Product and Pipeline Developments

• Decipher is the leading prostate cancer diagnostic, with over 300,000 patients tested, 33% U.S. market penetration, and 15 consecutive quarters of 20%+ volume growth.

• Decipher’s clinical evidence base continues to expand, supporting sustained growth into 2026 and beyond, with new predictive signatures (PORTOS, PTEN, PAM50) and digital pathology initiatives.

• Afirma has tested over 400,000 patients, sparing more than 250,000 from unnecessary surgery, and achieved 11% volume growth and 38% U.S. market penetration in thyroid diagnostics.

• Prosigna targets over 225,000 eligible U.S. breast cancer patients annually, with positive OPTIMA PRELIM data and LDT launch anticipated mid-2026.

• TrueMRD platform launching for muscle invasive bladder cancer in 1H 2026, with annual new indications expected from 2027 and robust clinical study pipeline.